INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 446m ago
HOUSE PTR46m ago
SEC 13F46m ago
ROBINHOOD CHAIN46m ago
SEC FORM 4/Grant or awardVerified data

Barretto-Ko Percival reported SPRB

Director · SPRUCE BIOSCIENCES, INC. · SPRUCE BIOSCIENCES, INC. — Stock Option (Right to Buy)

Side
A
Value
—
Shares
800
Price
—
Executed
Dec 11, 2025
Disclosed
Dec 15, 2025
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Dec 11 executedDec 15, 2025 disclosed

SPRB · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SPRB

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    15
    WK
    Walbert KeliDirector
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    1,700 sh
    		May 21, 2026May 26, 2026
    traded May 21, 2026
    		+5dSEC FORM 4

    Evidence

    15
    BP
    Barretto-Ko PercivalDirector
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    1,700 sh
    		May 21, 2026May 26, 2026
    traded May 21, 2026
    		+5dSEC FORM 4

    Evidence

    19
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    400 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    19
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Disposition to issuer
    		D—
    400 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    19
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Option exercise
    		M—
    1,250 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    31
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Option exercise
    		M—
    1,250 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    19
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    5,000 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    19
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    266 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    19
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Disposition to issuer
    		D—
    266 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    9
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Tax withholding
    		F$49K
    608 sh
    		Dec 15, 2025Dec 17, 2025
    traded Dec 15, 2025
    		+2dSEC FORM 4

    Evidence

    15
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    1,666 sh
    		Dec 11, 2025Dec 17, 2025
    traded Dec 11, 2025
    		+6dSEC FORM 4

    Evidence

    15
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Disposition to issuer
    		D—
    1,666 sh
    		Dec 11, 2025Dec 17, 2025
    traded Dec 11, 2025
    		+6dSEC FORM 4

    Evidence

    9
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Option exercise
    		M—
    1,480 sh
    		Dec 15, 2025Dec 17, 2025
    traded Dec 15, 2025
    		+2dSEC FORM 4

    Evidence

    21
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Option exercise
    		M—
    1,196 sh
    		Dec 15, 2025Dec 17, 2025
    traded Dec 15, 2025
    		+2dSEC FORM 4

    Evidence

    13
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Option exercise
    		M—
    1,480 sh
    		Dec 15, 2025Dec 17, 2025
    traded Dec 15, 2025
    		+2dSEC FORM 4

    Evidence

    16
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Tax withholding
    		F$61K
    752 sh
    		Dec 15, 2025Dec 17, 2025
    traded Dec 15, 2025
    		+2dSEC FORM 4

    Evidence

    13
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Option exercise
    		M—
    1,196 sh
    		Dec 15, 2025Dec 17, 2025
    traded Dec 15, 2025
    		+2dSEC FORM 4

    Evidence

    9
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Disposition to issuer
    		D—
    10.0K sh
    		Dec 11, 2025Dec 15, 2025
    traded Dec 11, 2025
    		+4dSEC FORM 4

    Evidence

    9
    SV
    Simpson Camilla VDirector
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    173 sh
    		Dec 11, 2025Dec 15, 2025
    traded Dec 11, 2025
    		+4dSEC FORM 4

    Evidence

    9
    SV
    Simpson Camilla VDirector
    SPRBSPRUCE BIOSCIENCES, INC.
    Disposition to issuer
    		D—
    173 sh
    		Dec 11, 2025Dec 15, 2025
    traded Dec 11, 2025
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001978654-25-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 11, 2025
    Published
    Dec 15, 2025
    Ingested by INSIDER
    Nov 5, 04:27 UTC
    Last re-read
    Nov 5, 04:27 UTC

    Extracted facts

    Filer
    Barretto-Ko Percival
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    SPRUCE BIOSCIENCES, INC. — Stock Option (Right to Buy)
    Ticker
    SPRB
    Shares
    800
    Execution date (reported)
    Dec 11, 2025
    Owned after transaction
    800 shares
    Days from execution to publication
    4

    What this establishes

    Barretto-Ko Percival filed this Form 4 reporting a grant or award of SPRB on Dec 11, 2025. It became public on Dec 15, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Barretto-Ko Percivalcik:0001978654
    Issuer
    SPRUCE BIOSCIENCES, INC.cik:0001683553

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.